|
Biogen Idec finalise l’achat de l’intégralité des droits et du contrôle de TYSABRI®
BFMTV.COM Biogen Idec possède également le portefeuille le plus étendu du secteur pour la SEP avec des composés tels que le PLEGRIDY™ (peginterféron bêta-1a) ; le processus à haut rendement du daclizumab (DAC HYP) pour une administration sous-cutanée … |
|
Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®
Financial Post Biogen Idec also has the deepest MS pipeline in the industry with compounds that include PLEGRIDY™ (peginterferon beta-1a); daclizumab high-yield process (DAC HYP) for monthly subcutaneous administration; and an ongoing study with TYSABRI as a … |
|
How Antibodies Neutralize Mosquito-Borne Virus
Science Daily (press release) The scientists used a technique called cryoelectron microscopy to uncover critical structural details about the virus-like particles bound to the antibodies. The particles are made of 180 “heterodimers,” molecules made of two proteins: envelope protein … |
|
New Promise for an HIV Vaccine as Researchers Overcome Crucial Obstacle
Science Daily (press release) Apr. 1, 2013 — In a crucial step towards developing a successful HIV vaccine, researchers have been able, for the first time, to stimulate immune cells that can produce broadly neutralizing antibodies: a feat that has eluded vaccine researchers for … |
 Genetic Engineering News |
Electronics Giants Set Sights on Biotech
Genetic Engineering News Last October, the company halted development of a biosimilar version of the Roche/Biogen Idec lymphoma and rheumatoid arthritis drug Rituxan (rituximab)—just six months after Tae-Han Kim, president of Samsung Biologics, told the Financial Times the … |
|
Promising stem cell therapy for leukemia patients
Medical Xpress Scientists are studying how antibodies can best protect the healthy tissue of leukemia patients. Credit: Dirk Mahler. Leukemia patients receive a bone marrow transplant, which allows them to build a “new” immune system. However, this immune system not … |
Genetic Engineering News |
Electronics Giants Think Biotech
Genetic Engineering News Last October, the company halted development of a biosimilar version of the Roche/Biogen Idec lymphoma and rheumatoid arthritis drug Rituxan (rituximab)—just six months after Tae-Han Kim, president of Samsung Biologics, told the Financial Times the … |
Research and Markets: Competitor Analysis: Her2 Antibodies – Trastuzumab …The Herald | HeraldOnline.comThe present Competitive Intelligence Report about Her2 Antibodies – Trastuzumab Biosimilars and Biobetters/Biosuperiors provides a competitor evalu…
Can Spectrum Pharmaceuticals Regain Investor Trust?Seeking AlphaThe Zevalin therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled Zevalin for therapy. The Zevalin therapeutic regimen is a form of cancer therapy c…
Rituximab reduced atherosclerosis progression in RA patientsHealioRituximab therapy reduced the progression of accelerated atherosclerosis in patients with rheumatoid arthritis, according to study results. Researchers in Italy studied 38 patients with …